|
TNFRSF10B
|
Glioblastoma
|
0.100 |
Biomarker |
LHGDN |
As TRAIL-R2 is more expressed, in comparison with TRAIL-R1, on GBM tumor cells, TRAIL-R2 seems to be of more importance as a target for future TRAIL therapy than TRAIL-R1.
|
16544055 |
2006 |
|
TNFRSF10B
|
Liver carcinoma
|
0.090 |
AlteredExpression |
LHGDN |
Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
|
12642868 |
2003 |
|
TNFRSF10B
|
B-Cell Lymphomas
|
0.070 |
GeneticVariation |
LHGDN |
Gene expression analysis and quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) showed down-regulation of TRAIL-R1 and TRAIL-R2 receptor genes as a consistent event in B-NHL with 8p21.3 loss.
|
16051735 |
2005 |
|
TNFRSF10B
|
melanoma
|
0.060 |
AlteredExpression |
LHGDN |
TRAIL-R1 and TRAIL-R2 expression exceeding the 95th percentile for nevi was found in 19% and 74% of melanoma specimens, respectively.
|
16778114 |
2006 |
|
TNFRSF10B
|
Glioma
|
0.040 |
Biomarker |
LHGDN |
Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
|
18341587 |
2008 |
|
TNFRSF10B
|
Osteosarcoma
|
0.040 |
AlteredExpression |
LHGDN |
Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells.
|
16571651 |
2006 |
|
TNFRSF10B
|
leukemia
|
0.030 |
AlteredExpression |
LHGDN |
The role of TRAIL death receptors in the treatment of hematological malignancies.
|
18203008 |
2008 |
|
TNFRSF10B
|
Mammary Neoplasms
|
0.030 |
AlteredExpression |
LHGDN |
RRR-gamma-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling.
|
18022315 |
2008 |
|
TNFRSF10B
|
Mammary Neoplasms
|
0.030 |
Biomarker |
LHGDN |
TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
|
19074831 |
2008 |
|
TNFRSF10B
|
Infection
|
0.030 |
Biomarker |
LHGDN |
Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
|
16226105 |
2005 |
|
TNFRSF10B
|
Infection
|
0.030 |
AlteredExpression |
LHGDN |
Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand.
|
15784899 |
2005 |
|
TNFRSF10B
|
Infection
|
0.030 |
AlteredExpression |
LHGDN |
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.
|
12915532 |
2003 |
|
TNFRSF10B
|
Lymphoma
|
0.020 |
AlteredExpression |
LHGDN |
The role of TRAIL death receptors in the treatment of hematological malignancies.
|
18203008 |
2008 |
|
TNFRSF10B
|
Rhabdomyosarcoma
|
0.020 |
AlteredExpression |
LHGDN |
A novel bioassay for B-cell activating factor (BAFF) based on expression of a BAFF-receptor ectodomain-tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-2 endodomain fusion receptor in human rhabdomyosarcoma cells.
|
18625509 |
2008 |
|
TNFRSF10B
|
Adenocarcinoma
|
0.020 |
AlteredExpression |
LHGDN |
Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3.
|
17689858 |
2007 |
|
TNFRSF10B
|
Lung Neoplasms
|
0.020 |
AlteredExpression |
LHGDN |
Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells.
|
17548900 |
2007 |
|
TNFRSF10B
|
Leukemia, Myelocytic, Acute
|
0.020 |
Biomarker |
LHGDN |
In non-APL AML we observed frequent expression of TRAIL decoy receptors (TRAIL-R3 and TRAIL-R4), while TRAIL-R1 and TRAIL-R2 expression was restricted to AML exhibiting monocytic features.
|
15921376 |
2005 |
|
TNFRSF10B
|
Rheumatoid Arthritis
|
0.020 |
AlteredExpression |
LHGDN |
TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis.
|
12847280 |
2003 |
|
TNFRSF10B
|
Hematologic Neoplasms
|
0.010 |
AlteredExpression |
LHGDN |
The role of TRAIL death receptors in the treatment of hematological malignancies.
|
18203008 |
2008 |
|
TNFRSF10B
|
Anoxia
|
0.010 |
AlteredExpression |
LHGDN |
Hypoxia/reoxygenation up-regulated the expression of death receptor 5 and enhanced apoptosis in human hepatocyte line.
|
16980044 |
2006 |
|
TNFRSF10B
|
Dengue Fever
|
0.010 |
AlteredExpression |
LHGDN |
Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand.
|
15784899 |
2005 |
|
TNFRSF10B
|
Mesothelioma
|
0.010 |
AlteredExpression |
LHGDN |
FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells.
|
15334061 |
2004 |
|
TNFRSF10B
|
Pancreatitis, Chronic
|
0.010 |
Biomarker |
LHGDN |
In chronic pancreatitis, widespread emergence of TRAIL receptors in epithelia coincides with neoexpression of TRAIL by pancreatic stellate cells of early fibrotic areas.
|
12808117 |
2003 |